NASDAQ OMX

NuVinci® Cycling Advances Service Solution for Switzerland and France

Dela

 

Service for the French and Swiss markets to be handled by NuVinci Cycling's International Service Center

AMSTERDAM, NETHERLANDS / CEDAR PARK, TEXAS, Aug. 28, 2017 (GLOBE NEWSWIRE) --

Based on its mission "to move people better," NuVinci Cycling, a division of Fallbrook Technologies Inc., aims to get riders back on their bike as quickly as possible in case something goes wrong with their NuVinci Optimized(TM) bicycle, regardless of their location. With this in mind, and given the company's remarkable growth in France and Switzerland, NuVinci Cycling is advancing its service offering in those local markets to provide a better and more direct after-sales experience. Beginning September 1st, 2017, service for France and Switzerland will be managed by NuVinci Cycling's International Service Center in The Netherlands. The updates to the service structure brings multiple advantages, including optimized availability of spare parts, improved service team availability, a more direct connection to internal product experts, as well as a more effective service process.

Recently, the French market has seen a significant increase in its eBike sales, thus raising a new challenge for both OEMs and dealers operating in that market to offer fast and good quality services to their end-consumers. "To meet riders' expectations of having their bicycles running smoothly at any time, we now want to support partner OEMs by expanding the reach of our Service Center to now also include the French market," says Billy van den Ende, Sales Director at NuVinci Cycling. French dealers and OEMs can reach the Service Center in the Netherlands by e-mail: FR-service@nuvincicyling.com  or phone: +33 97 073 13 34.

Service in Switzerland was previously handled by Ofelec AG. Since the demand for NuVinci Optimized bikes and eBikes has grown significantly since the relationship began, the need for an even more direct contact has arisen. As a result, retailers can only order spare parts through the website www.nuvinci.com/eurosales going forward. Dealers and manufacturers in Switzerland and Lichtenstein can contact NuVinci Cycling's Service Center by email: CH-service@nuvincicycling.com or phone: +41 43 508 55 97.

About NuVinci® Cycling

NuVinci Cycling, a division of Fallbrook Technologies Inc., moves people better throughits product portfolio of smooth, stepless, automatic, and integrated shifting products for bicycles and eBikes. The NuVinci technology incorporated in continuously variable transmissions (CVT) for bicycles has been providing the best rider experiences since 2006. NuVinci Optimized(TM) cycling products include the Nfinity(TM) and Harmony(TM) groupsets, utilizing the latest versions of the transmissions and controllers. Products from NuVinci Cycling, the leader in CVTs for bikes and eBIkes, are available globally in over 100 bicycle brands. For more information, visit www.nuvincicycling.com.

About Fallbrook Technologies

Fallbrook Technologies is the inventor of the revolutionary NuVinci® continuously variable planetary (CVP) technology, which enables performance and efficiencyimprovements for machines that use an engine, pump, motor, or geared transmissionsystem - including urban mobility vehicles, cars and trucks, industrial equipment, andmany other applications. Fallbrook has a unique collective development model andcommunity through which NuVinci technology licensees share enhancements, which adds to the value of the technology and accelerates product development. This approach enables forward-looking companies, who wish to create visionary new products with NuVinci technology, to move quickly from concept to market commercialization. Fallbrook is based in Cedar Park near Austin, Texas, USA and holds rights to over 800 patents and patent applications worldwide. For more information, visit www.fallbrooktech.com.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1f381fc7-b1c5-4682-a1fe-24c6268164ed

Anne Guethoff
NuVinci Cycling 
+ 49 160 92290159
Anne.Guethoff@nuvincicycling.com
 
 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NuVinci Cycling via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste pressmeddelandena från NASDAQ OMX

XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00Pressmeddelande

AUSTIN, Texas, Sept.  21, 2017  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech

At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58Pressmeddelande

LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service.  As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al

Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00Pressmeddelande

Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00Pressmeddelande

Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea

Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00Pressmeddelande

Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu

Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23Pressmeddelande

DANVERS, Mass., Sept.  20, 2017  (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum